123 related articles for article (PubMed ID: 18926796)
21. Colocalization of interferon regulatory factor 7 (IRF7) with latent membrane protein 1 (LMP1) of Epstein-Barr virus.
Kim IW; Park HS
J Korean Med Sci; 2006 Jun; 21(3):379-84. PubMed ID: 16778376
[TBL] [Abstract][Full Text] [Related]
22. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the rapamycin-inducible EBV LMP1 activation system.
Kim SY; Kim JE; Won J; Song YJ
J Microbiol; 2015 Oct; 53(10):732-8. PubMed ID: 26428925
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.
Kilger E; Kieser A; Baumann M; Hammerschmidt W
EMBO J; 1998 Mar; 17(6):1700-9. PubMed ID: 9501091
[TBL] [Abstract][Full Text] [Related]
25. The latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus induces expression of the putative oncogene Bcl-3 through activation of the nuclear factor-kappaB.
Nakamura H; Ishii C; Suehiro M; Iguchi A; Kuroda K; Shimizu K; Shimizu N; Imadome K; Yajima M; Fujiwara S
Virus Res; 2008 Feb; 131(2):170-9. PubMed ID: 17963943
[TBL] [Abstract][Full Text] [Related]
26. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.
Forte E; Salinas RE; Chang C; Zhou T; Linnstaedt SD; Gottwein E; Jacobs C; Jima D; Li QJ; Dave SS; Luftig MA
J Virol; 2012 Jun; 86(12):6889-98. PubMed ID: 22496226
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.
Kim JH; Kim WS; Park C
Leuk Lymphoma; 2012 Aug; 53(8):1586-91. PubMed ID: 22268450
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma.
Kim JH; Kim WS; Park C
Leuk Lymphoma; 2013 Sep; 54(9):2035-40. PubMed ID: 23363221
[TBL] [Abstract][Full Text] [Related]
29. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
30. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence.
Lu F; Weidmer A; Liu CG; Volinia S; Croce CM; Lieberman PM
J Virol; 2008 Nov; 82(21):10436-43. PubMed ID: 18753206
[TBL] [Abstract][Full Text] [Related]
33. Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1.
Zhou H; Guo W; Long C; Wang H; Wang J; Sun X
Biochem Biophys Res Commun; 2015 Jan; 456(3):815-20. PubMed ID: 25511707
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
35. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
36. Latent membrane protein 1 of Epstein-Barr virus sensitizes cancer cells to cisplatin by enhancing NF-κB p50 homodimer formation and downregulating NAPA expression.
Wu ZZ; Chow KP; Kuo TC; Chang YS; Chao CC
Biochem Pharmacol; 2011 Dec; 82(12):1860-72. PubMed ID: 21945668
[TBL] [Abstract][Full Text] [Related]
37. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1).
Eliopoulos AG; Young LS
Oncogene; 1998 Apr; 16(13):1731-42. PubMed ID: 9582021
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
Vockerodt M; Tesch H; Kube D
Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
[TBL] [Abstract][Full Text] [Related]
39. Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway.
Wu X; Liu P; Zhang H; Li Y; Salmani JM; Wang F; Yang K; Fu R; Chen Z; Chen B
BMC Cancer; 2017 Feb; 17(1):147. PubMed ID: 28222771
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
